PEOPLE - Changes at MWG Biotech AG (Germany):
This article was originally published in Clinica
Ebersburg, Germany-based MWG Biotech AG has announced the resignation of Thomas Becker from his position as chairman of the board, effective immediately. Mr Becker has cited personal reasons for his departure. Until a successor is appointed, Dr Wolfgang Pieken will add finance and investor relations to his role as chief officer of US business, and Dr Volker Muschalek will add personal and IT sectors to his COO responsibilites.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.